Jump to content

2-Oxazolidinone: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
ce
OAbot (talk | contribs)
Bots
437,752 edits
m Open access bot: doi updated in citation with #oabot.
(13 intermediate revisions by 2 users not shown)
Line 7: Line 7:
| ImageName =
| ImageName =
| PIN = 1,3-Oxazolidin-2-one
| PIN = 1,3-Oxazolidin-2-one
| OtherNames = 2-Oxazolidone<br />2-Oxazolidinone
| OtherNames = 1,3-Oxazolidin-2-one, 2-Oxo-1,3-oxazolidine, 2-Oxotetrahydro-1,3-oxazole
|Section1={{Chembox Identifiers
|Section1={{Chembox Identifiers
| SMILES = O=C1OCCN1
| SMILES = O=C1OCCN1
Line 30: Line 30:
| Formula = C<sub>3</sub>H<sub>5</sub>NO<sub>2</sub>
| Formula = C<sub>3</sub>H<sub>5</sub>NO<sub>2</sub>
| MolarMass = 87.077 g/mol
| MolarMass = 87.077 g/mol
| Appearance = Solid
| Appearance = white or colorless solid
| Density =
| Density =
| Solubility =
| Solubility =
Line 53: Line 53:
}}
}}


'''2-Oxazolidone''' is a [[Heterocyclic compound|heterocyclic]] [[organic compound]] containing both nitrogen and oxygen in a 5-membered ring. It is one of waste products generated in [[amine gas treating]] due to cyclization of [[ethanolamine]] carbamate.<ref>{{Cite journal |last=Salim |first=S. R. S. |date=2021-03-01 |title=Treatment of amine wastes generated in industrial processes |url=https://iopscience.iop.org/article/10.1088/1757-899X/1092/1/012051 |journal=IOP Conference Series: Materials Science and Engineering |volume=1092 |issue=1 |pages=012051 |doi=10.1088/1757-899x/1092/1/012051 |issn=1757-8981}}</ref>
'''2-Oxazolidinone''' is a [[Heterocyclic compound|heterocyclic]] [[organic compound]] containing both nitrogen and oxygen in a 5-membered ring.


== History ==
== Synthesis and occurence==
The compound arises by the reaction of an ethanolamine and dimethylcarbonate<ref>{{cite journal |doi=10.15227/orgsyn.062.0149 |title=Synthesis and Diels–Alder Rearctions of 3-Acetyl-2(3H)-Oxazolone: 6-Amino-3,4-dimethyl-cis-3-cyclohexen-1-ol |journal=Organic Syntheses |date=1984 |volume=62 |page=149|author=
⚫
The compound was first synthesized in 1888 by German chemist [[Siegmund Gabriel]]. While investigating reactions of bromoethylamine hydrobromide, he treated it with [[silver carbonate]] and isolated a product with melting point around 90–91°C. He determined its empirical formula correctly, but neither gave it a specific name not studied its properties.<ref>{{Cite journal |last=Gabriel |first=S. |date=1888 |title=Ueber einige Derivate des Aethylamins |url=https://books.google.com/books?id=d_1hofkLJ-wC&pg=PA568 |journal=Berichte der deutschen chemischen Gesellschaft |language=de |volume=21 |issue=1 |pages=566–575 |doi=10.1002/cber.188802101103 |issn=0365-9496}}</ref>
Karl-Heinz Scholz, Hans-Georg Heine, Willy Hartmann }}</ref> or related [[phosgene]] equivalents.<ref>{{cite journal |doi=10.15227/orgsyn.075.0045 |title=(4R,5S)-4,5-Diphenyl-3-Vinyl-2-Oxazolidinone |journal=Organic Syntheses |date=1998 |volume=75 |page=45|author=T. Akiba, O. Tamura, S. Terashima }}</ref>


It is one of waste products generated in [[amine gas treating]] due to cyclization of [[ethanolamine]] carbamate.<ref>{{Cite journal |last=Salim |first=S. R. S. |date=2021-03-01 |title=Treatment of amine wastes generated in industrial processes |url=https://iopscience.iop.org/article/10.1088/1757-899X/1092/1/012051 |journal=IOP Conference Series: Materials Science and Engineering |volume=1092 |issue=1 |pages=012051 |doi=10.1088/1757-899x/1092/1/012051 |issn=1757-8981|doi-access=free }}</ref>
⚫
16 years later Gabriel returned to the topic together with G. Eschenbach, developing a more efficient synthesis using [[sodium bicarbonate]] instead of the silver salt. They referred to the compound as "Oxäthylcarbaminsäureanhydrid" (hydroxyethylcarbamic acid anhydride), recognizing its relationship to ethanolamine and its cyclic structure. Their 1897 paper focused on optimizing the yield of oxazolidone and investigating some of its reactions, such as its conversion to 1-(2-hydroxyethyl)-3-phenylurea upon treatment with aniline.<ref>{{Cite journal |last=Gabriel |first=S. |last2=Eschenbach |first2=G. |date=September 1897 |title=Notizen über Bromäthylamin und Vinylamin |url=https://books.google.com/books?id=jAvVlrHhI1kC&pg=PA2494 |journal=Berichte der deutschen chemischen Gesellschaft |language=de |volume=30 |issue=3 |pages=2494–2497 |doi=10.1002/cber.18970300324 |issn=0365-9496}}</ref>
⚫
===History===
⚫
The compound was first reported in 1888 by German chemist [[Siegmund Gabriel]]. While investigating reactions of bromoethylamine hydrobromide, he treated it with [[silver carbonate]] and isolated a product with melting point around 90–91°C. He determined its empirical formula correctly, but neither gave it a specific name not studied its properties.<ref>{{Cite journal |last=Gabriel |first=S. |date=1888 |title=Ueber einige Derivate des Aethylamins |url=https://books.google.com/books?id=d_1hofkLJ-wC&pg=PA568 |journal=Berichte der Deutschen Chemischen Gesellschaft |language=de |volume=21 |issue=1 |pages=566–575 |doi=10.1002/cber.188802101103 |issn=0365-9496}}</ref>


⚫
Nine years later Gabriel returned to the topic together with G. Eschenbach, developing a more efficient synthesis using [[sodium bicarbonate]] instead of the silver salt. They referred to the compound as "Oxäthylcarbaminsäureanhydrid" (hydroxyethylcarbamic acid anhydride), recognizing its relationship to ethanolamine and its cyclic structure. Their 1897 paper focused on optimizing the yield of oxazolidone and investigating some of its reactions, such as its conversion to 1-(2-hydroxyethyl)-3-phenylurea upon treatment with aniline.<ref>{{Cite journal |last1=Gabriel |first1=S. |last2=Eschenbach |first2=G. |date=September 1897 |title=Notizen über Bromäthylamin und Vinylamin |url=https://books.google.com/books?id=jAvVlrHhI1kC&pg=PA2494 |journal=Berichte der Deutschen Chemischen Gesellschaft |language=de |volume=30 |issue=3 |pages=2494–2497 |doi=10.1002/cber.18970300324 |issn=0365-9496}}</ref>
==Oxazolidinones==

==Substituted oxazolidinones==


===Evans auxiliaries===
===Evans auxiliaries===
Oxazolidinones are a class of compounds containing 2-oxazolidone in the structure. In chemistry, they are useful as [[Aldol reaction#Evans' oxazolidinone chemistry|Evans auxiliaries]], which are used for [[chiral synthesis]]. Usually, the [[acid chloride]] substrate reacts with the oxazolidinone to form an [[imide]]. Substituents at the 4 and 5 position of the oxazolidinone direct any [[aldol reaction]] to the alpha position of the carbonyl of the substrate.{{cn|date=March 2023}}
Oxazolidinones are useful as [[Aldol reaction#Evans' oxazolidinone chemistry|Evans auxiliaries]], which are of interest for [[chiral synthesis]]. In a common implementation, an [[acid chloride]] substrate reacts with a chiral oxazolidinone to form an [[imide]]. Substituents at the 4 and 5 position of the oxazolidinone direct any [[aldol reaction]] to the alpha position of the carbonyl of the substrate.<ref>{{cite journal |doi=10.15227/orgsyn.068.0083 |title=Diastereoselective Aldol Condensation Using a Chiral Oxazolidinone Auxiliary: (2S,3S)-3-Hydroxy-3-Phenyl-2-Methylpropanoic Acid |journal=Organic Syntheses |date=1990 |volume=68 |page=83|author=James R. Gage, David A. Evans }}</ref> Asymmetric Diels-Alder reactions are also enabled by these auxilliaries.<ref>{{cite journal |doi=10.15227/orgsyn.071.0030 |title=Enantioselective, Catlytic Diels-Alder Reaction: (1S-endo)-3-(Bicyclo&#91;2.2.1&#93;Hept-5-en-2-ylcarbonyl)-2-Oxazolidinone |journal=Organic Syntheses |date=1993 |volume=71 |page=30|author=S. Pikul, E. J. Corey }}</ref>


===Pharmaceuticals===
===Pharmaceuticals===
Oxazolidinones are mainly used as antimicrobials. The antibacterial effect of oxazolidinones is by working as [[protein synthesis inhibitor]]s, targeting an early step involving the binding of N-formylmethionyl-tRNA to the ribosome.<ref>{{Cite journal
Oxazolidinones are found in some antimicrobials. Oxazolidinones [[protein synthesis inhibitor|inhibit protein synthesis]] by interfering with the binding of N-formylmethionyl-tRNA to the ribosome.<ref>{{Cite journal
| last1 = Shinabarger | first1 = D.
| last1 = Shinabarger | first1 = D.
| doi = 10.1517/13543784.8.8.1195
| doi = 10.1517/13543784.8.8.1195
Line 81: Line 86:
|author=Sonia Ilaria Maffioli|editor1 = Claudio O. Gualerzi |editor2=Letizia Brandi |editor3=Attilio Fabbretti |editor4=Cynthia L. Pon|year=2014|publisher=Wiley-VCH|isbn=9783527659685}}</ref>
|author=Sonia Ilaria Maffioli|editor1 = Claudio O. Gualerzi |editor2=Letizia Brandi |editor3=Attilio Fabbretti |editor4=Cynthia L. Pon|year=2014|publisher=Wiley-VCH|isbn=9783527659685}}</ref>


Examples of antibiotic oxazolidinones include:
Examples of oxazolidinone-containing antibiotics:
* [[Linezolid]] (Zyvox), which is available for [[intravenous]] administration and also has the advantage of having excellent oral [[bioavailability]].
* [[Linezolid]] (Zyvox), which is available for [[intravenous]] administration and also has the advantage of having excellent oral [[bioavailability]].
* [[Posizolid]], which appears to have excellent, targeted bactericidal activity against all common gram-positive bacteria, regardless of resistance to other classes of antibiotics.<ref>{{cite journal |author1=Wookey, A. |author2=Turner, P. J. |author3=Greenhalgh, J. M. |author4=Eastwood, M. |author5=Clarke, J. |author6=Sefton, C. | title = AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro | journal = Clinical Microbiology and Infection | year = 2004 | volume = 10 | issue = 3 | pages = 247–254 | pmid=15008947 | doi = 10.1111/j.1198-743X.2004.00770.x| doi-access=free }}</ref>
* [[Posizolid]], which appears to have excellent, targeted bactericidal activity against all common gram-positive bacteria, regardless of resistance to other classes of antibiotics.<ref>{{cite journal |author1=Wookey, A. |author2=Turner, P. J. |author3=Greenhalgh, J. M. |author4=Eastwood, M. |author5=Clarke, J. |author6=Sefton, C. | title = AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro | journal = Clinical Microbiology and Infection | year = 2004 | volume = 10 | issue = 3 | pages = 247–254 | pmid=15008947 | doi = 10.1111/j.1198-743X.2004.00770.x| doi-access=free }}</ref>
Line 87: Line 92:
* [[Tedizolid]], (Sivextro) which is approved for acute skin infections
* [[Tedizolid]], (Sivextro) which is approved for acute skin infections
* [[Radezolid]] (RX-1741) has completed some phase-II clinical trials.<ref>{{cite web|url=http://www.rib-x.com/pipeline/rx_1741 |title=Rx 1741 |publisher=Rib-X Pharmaceuticals |year=2009 |access-date=2009-05-17 |url-status=dead |archive-url=https://web.archive.org/web/20090226201337/http://www.rib-x.com/pipeline/rx_1741 |archive-date=2009-02-26 }}</ref>
* [[Radezolid]] (RX-1741) has completed some phase-II clinical trials.<ref>{{cite web|url=http://www.rib-x.com/pipeline/rx_1741 |title=Rx 1741 |publisher=Rib-X Pharmaceuticals |year=2009 |access-date=2009-05-17 |url-status=dead |archive-url=https://web.archive.org/web/20090226201337/http://www.rib-x.com/pipeline/rx_1741 |archive-date=2009-02-26 }}</ref>
* [[Cycloserine]] is a second line drug against [[tuberculosis]]. Note that cycloserine, while technically an oxazolidone, has a different mechanism of action and substantially different properties from the aforementioned compounds.
* [[Contezolid]] (MRX-I) has reported phase 1 data<ref>{{cite journal|doi=10.1021/jm401931e | volume=57 | issue=11 | title=New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile | year=2014 | journal=Journal of Medicinal Chemistry | pages=4487–4497 | last1 = Gordeev | first1 = Mikhail F. | last2 = Yuan | first2 = Zhengyu Y.| pmid=24694071 }}</ref> and phase III data.<ref>{{cite journal | doi = 10.1093/jac/dkac073 | title = A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections | year = 2022 | last1 = Zhao | first1 = Xu | last2 = Huang | first2 = Haihui | last3 = Yuan | first3 = Hong | last4 = Yuan | first4 = Zhengyu | last5 = Zhang | first5 = Yingyuan | journal = Journal of Antimicrobial Chemotherapy | volume = 77 | issue = 6 | pages = 1762–1769 | pmid = 35265985 }}</ref> In 2021, a new drug summary was published by ADIS Press.<ref>{{Cite journal | doi = 10.1007/s40265-021-01576-0 | title = Contezolid: First Approval | year = 2021 | last1 = Hoy | first1 = Sheridan M. | journal = Drugs | volume = 81 | issue = 13 | pages = 1587–1591 | pmid = 34365606 | pmc = 8536612 }}</ref> In June 2021, marketing approval was granted by the Chinese National Medical Products Administration (NMPA) for use of oral contezolid in moderate to severe complicated skin and skin structure infections.<ref>{{cite web | url = http://www.micurx.com/703.html | title = China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection – MicuRx Pharmaceuticals, Inc }}</ref> In June 2022, contezolid oral tablets and contezolid acefosamil IV (a prodrug of contezolid) began Phase 3 global clinical trials in moderate to severe diabetic foot infections.<ref>ClinicalTrials.gov Identifier: NCT05369052 </ref> An additional global Phase 3 study is planned for acute bacterial skin and skin structure infections (ABSSSI) for the combination of contezolid and contezolid acefosamil.
* [[Contezolid]] (MRX-I) has reported phase 1 data<ref>{{cite journal|doi=10.1021/jm401931e | volume=57 | issue=11 | title=New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile | year=2014 | journal=Journal of Medicinal Chemistry | pages=4487–4497 | last1 = Gordeev | first1 = Mikhail F. | last2 = Yuan | first2 = Zhengyu Y.| pmid=24694071 }}</ref> and phase III data.<ref>{{cite journal | doi = 10.1093/jac/dkac073 | title = A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections | year = 2022 | last1 = Zhao | first1 = Xu | last2 = Huang | first2 = Haihui | last3 = Yuan | first3 = Hong | last4 = Yuan | first4 = Zhengyu | last5 = Zhang | first5 = Yingyuan | journal = Journal of Antimicrobial Chemotherapy | volume = 77 | issue = 6 | pages = 1762–1769 | pmid = 35265985 }}</ref> In 2021, a new drug summary was published by ADIS Press.<ref>{{Cite journal | doi = 10.1007/s40265-021-01576-0 | title = Contezolid: First Approval | year = 2021 | last1 = Hoy | first1 = Sheridan M. | journal = Drugs | volume = 81 | issue = 13 | pages = 1587–1591 | pmid = 34365606 | pmc = 8536612 }}</ref> In June 2021, marketing approval was granted by the Chinese National Medical Products Administration (NMPA) for use of oral contezolid in moderate to severe complicated skin and skin structure infections.<ref>{{cite web | url = http://www.micurx.com/703.html | title = China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection – MicuRx Pharmaceuticals, Inc }}</ref> In June 2022, contezolid oral tablets and contezolid acefosamil IV (a prodrug of contezolid) began Phase 3 global clinical trials in moderate to severe diabetic foot infections.<ref>ClinicalTrials.gov Identifier: NCT05369052 </ref> An additional global Phase 3 study is planned for acute bacterial skin and skin structure infections (ABSSSI) for the combination of contezolid and contezolid acefosamil.
* An oxazolidinone derivative used for other purposes is [[rivaroxaban]], which is approved by the FDA for venous thromboembolism prophylaxis.
* An oxazolidinone derivative used for other purposes is [[rivaroxaban]], which is approved by the U.S. FDA for venous thromboembolism prophylaxis.

⚫
====History====
[[Image:Cycloserine.svg|thumb|left|125px|Chemical structure of cycloserine]] The first ever used oxazolidinone was [[cycloserine]] (''4-amino-1,2-oxazolidin-3-one''), a second line drug against tuberculosis since 1956.<ref name=hager>A. W. Frahm, H. H. J. Hager, F. v. Bruchhausen, M. Albinus, H. Hager: ''Hagers Handbuch der pharmazeutischen Praxis: Folgeband 4: Stoffe A–K.'', Birkhäuser, 1999, {{ISBN|978-3-540-52688-9}}</ref>

Developed during the nineties when several bacterial strains were becoming resistant against such antibiotics as [[vancomycin]]. [[Linezolid]] (Zyvox) is the first approved agent in the class (FDA approval April 2000).
{{clear|left}}


[[Image:Linezolid.svg|thumb|200px|right|Chemical structure of linezolid]]
[[Image:Linezolid.svg|thumb|200px|right|Chemical structure of linezolid]]
The first commercially available 1,3-oxazolidinone antibiotic was [[linezolid]], discovered and developed by [[Pharmacia & Upjohn]].{{cn|date=March 2023}}
A first commercially available 1,3-oxazolidinone is the antibiotic [[linezolid]].

[[Image:Posizolid.svg|thumb|300px|left|Chemical structure of posizolid]]
In 2002 [[AstraZeneca]] began investigating [[posizolid]], which is in clinical trials for use in humans.<ref>{{cite journal |last1=Karpiuk |first1=I |last2=Tyski |first2=S |title=Looking for the new preparations for antibacterial therapy. V. New antimicrobial agents from the oxazolidinones groups in clinical trials |journal=Przeglad Epidemiologiczny |date=2017 |volume=71 |issue=2 |pages=207–219 |pmid=28872286}}</ref>

{{clear}}


==See also==
==See also==

Revision as of 05:16, 2 December 2024

2-Oxazolidone
Names
Preferred IUPAC name
1,3-Oxazolidin-2-one
Other names
1,3-Oxazolidin-2-one, 2-Oxo-1,3-oxazolidine, 2-Oxotetrahydro-1,3-oxazole
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.007.129 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5) checkY
    Key: IZXIZTKNFFYFOF-UHFFFAOYSA-N checkY
  • InChI=1/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)
    Key: IZXIZTKNFFYFOF-UHFFFAOYAE
  • O=C1OCCN1
Properties
C3H5NO2
Molar mass 87.077 g/mol
Appearance white or colorless solid
Melting point 86 to 89 °C (187 to 192 °F; 359 to 362 K)
Boiling point 220 °C (428 °F; 493 K) at 48 torr
Related compounds
Related compounds
 Oxazolidine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

2-Oxazolidinone is a heterocyclic organic compound containing both nitrogen and oxygen in a 5-membered ring.

Synthesis and occurence

The compound arises by the reaction of an ethanolamine and dimethylcarbonate[1] or related phosgene equivalents.[2]

It is one of waste products generated in amine gas treating due to cyclization of ethanolamine carbamate.[3]

History

The compound was first reported in 1888 by German chemist Siegmund Gabriel. While investigating reactions of bromoethylamine hydrobromide, he treated it with silver carbonate and isolated a product with melting point around 90–91°C. He determined its empirical formula correctly, but neither gave it a specific name not studied its properties.[4]

Nine years later Gabriel returned to the topic together with G. Eschenbach, developing a more efficient synthesis using sodium bicarbonate instead of the silver salt. They referred to the compound as "Oxäthylcarbaminsäureanhydrid" (hydroxyethylcarbamic acid anhydride), recognizing its relationship to ethanolamine and its cyclic structure. Their 1897 paper focused on optimizing the yield of oxazolidone and investigating some of its reactions, such as its conversion to 1-(2-hydroxyethyl)-3-phenylurea upon treatment with aniline.[5]

Substituted oxazolidinones

Evans auxiliaries

Oxazolidinones are useful as Evans auxiliaries, which are of interest for chiral synthesis. In a common implementation, an acid chloride substrate reacts with a chiral oxazolidinone to form an imide. Substituents at the 4 and 5 position of the oxazolidinone direct any aldol reaction to the alpha position of the carbonyl of the substrate.[6] Asymmetric Diels-Alder reactions are also enabled by these auxilliaries.[7]

Pharmaceuticals

Oxazolidinones are found in some antimicrobials. Oxazolidinones inhibit protein synthesis by interfering with the binding of N-formylmethionyl-tRNA to the ribosome.[8] (See Linezolid#Pharmacodynamics)

Some of the most important oxazolidinones are antibiotics.[9]

Examples of oxazolidinone-containing antibiotics:

  • Linezolid (Zyvox), which is available for intravenous administration and also has the advantage of having excellent oral bioavailability.
  • Posizolid, which appears to have excellent, targeted bactericidal activity against all common gram-positive bacteria, regardless of resistance to other classes of antibiotics.[10]
Chemical structure of tedizolid
  • Tedizolid, (Sivextro) which is approved for acute skin infections
  • Radezolid (RX-1741) has completed some phase-II clinical trials.[11]
  • Contezolid (MRX-I) has reported phase 1 data[12] and phase III data.[13] In 2021, a new drug summary was published by ADIS Press.[14] In June 2021, marketing approval was granted by the Chinese National Medical Products Administration (NMPA) for use of oral contezolid in moderate to severe complicated skin and skin structure infections.[15] In June 2022, contezolid oral tablets and contezolid acefosamil IV (a prodrug of contezolid) began Phase 3 global clinical trials in moderate to severe diabetic foot infections.[16] An additional global Phase 3 study is planned for acute bacterial skin and skin structure infections (ABSSSI) for the combination of contezolid and contezolid acefosamil.
  • An oxazolidinone derivative used for other purposes is rivaroxaban, which is approved by the U.S. FDA for venous thromboembolism prophylaxis.
Chemical structure of linezolid

A first commercially available 1,3-oxazolidinone is the antibiotic linezolid.

See also

References

  1. ^ Karl-Heinz Scholz, Hans-Georg Heine, Willy Hartmann (1984). "Synthesis and Diels–Alder Rearctions of 3-Acetyl-2(3H)-Oxazolone: 6-Amino-3,4-dimethyl-cis-3-cyclohexen-1-ol". Organic Syntheses. 62: 149. doi:10.15227/orgsyn.062.0149.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ T. Akiba, O. Tamura, S. Terashima (1998). "(4R,5S)-4,5-Diphenyl-3-Vinyl-2-Oxazolidinone". Organic Syntheses. 75: 45. doi:10.15227/orgsyn.075.0045.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Salim, S. R. S. (2021-03-01). "Treatment of amine wastes generated in industrial processes". IOP Conference Series: Materials Science and Engineering. 1092 (1): 012051. doi:10.1088/1757-899x/1092/1/012051. ISSN 1757-8981.
  4. ^ Gabriel, S. (1888). "Ueber einige Derivate des Aethylamins". Berichte der Deutschen Chemischen Gesellschaft (in German). 21 (1): 566–575. doi:10.1002/cber.188802101103. ISSN 0365-9496.
  5. ^ Gabriel, S.; Eschenbach, G. (September 1897). "Notizen über Bromäthylamin und Vinylamin". Berichte der Deutschen Chemischen Gesellschaft (in German). 30 (3): 2494–2497. doi:10.1002/cber.18970300324. ISSN 0365-9496.
  6. ^ James R. Gage, David A. Evans (1990). "Diastereoselective Aldol Condensation Using a Chiral Oxazolidinone Auxiliary: (2S,3S)-3-Hydroxy-3-Phenyl-2-Methylpropanoic Acid". Organic Syntheses. 68: 83. doi:10.15227/orgsyn.068.0083.
  7. ^ S. Pikul, E. J. Corey (1993). "Enantioselective, Catlytic Diels-Alder Reaction: (1S-endo)-3-(Bicyclo[2.2.1]Hept-5-en-2-ylcarbonyl)-2-Oxazolidinone". Organic Syntheses. 71: 30. doi:10.15227/orgsyn.071.0030.
  8. ^ Shinabarger, D. (1999). "Mechanism of action of the oxazolidinone antibacterial agents". Expert Opinion on Investigational Drugs. 8 (8): 1195–1202. doi:10.1517/13543784.8.8.1195. PMID 15992144.
  9. ^ Sonia Ilaria Maffioli (2014). "A Chemist's Survey of Different Antibiotic Classes". In Claudio O. Gualerzi; Letizia Brandi; Attilio Fabbretti; Cynthia L. Pon (eds.). Antibiotics: Targets, Mechanisms and Resistance. Wiley-VCH. ISBN 9783527659685.
  10. ^ Wookey, A.; Turner, P. J.; Greenhalgh, J. M.; Eastwood, M.; Clarke, J.; Sefton, C. (2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–254. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.
  11. ^ "Rx 1741". Rib-X Pharmaceuticals. 2009. Archived from the original on 2009-02-26. Retrieved 2009-05-17.
  12. ^ Gordeev, Mikhail F.; Yuan, Zhengyu Y. (2014). "New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile". Journal of Medicinal Chemistry. 57 (11): 4487–4497. doi:10.1021/jm401931e. PMID 24694071.
  13. ^ Zhao, Xu; Huang, Haihui; Yuan, Hong; Yuan, Zhengyu; Zhang, Yingyuan (2022). "A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections". Journal of Antimicrobial Chemotherapy. 77 (6): 1762–1769. doi:10.1093/jac/dkac073. PMID 35265985.
  14. ^ Hoy, Sheridan M. (2021). "Contezolid: First Approval". Drugs. 81 (13): 1587–1591. doi:10.1007/s40265-021-01576-0. PMC 8536612. PMID 34365606.
  15. ^ "China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection – MicuRx Pharmaceuticals, Inc".
  16. ^ ClinicalTrials.gov Identifier: NCT05369052
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=2-Oxazolidinone&oldid=1260710103"